Tislelizumab's inclusion in the National Comprehensive Cancer Network (NCCN) guidelines for hepatocellular carcinoma (HCC) as a category 1 recommendation marks an advancement in the treatment landscape for HCC.
Megan Hollasch
Advertisement
Articles by Megan Hollasch
Although HER2 amplification showed prognostic capabilities in patients with RAS wild-type metastatic colorectal cancer (mCRC), it was not predictive of survival benefit as a first-line treatment option in combination with panitumumab vs standard-of-care bevacizumab.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Sudden Death in HFpEF Often Preceded by Clinical Decline
2
FDA Issues Complete Response Letter for Cingulate's Once-Daily ADHD Drug CTx-1301
3
How Often Do Health Insurers Deny Doctor-Recommended Care?
4
New Data Support Pimicotinib as Durable for Rare Tenosynovial Giant Cell Tumor
5